PTEN and neoplasm: In the current study, to select anti-tumor drug candidates for a MIBC case harboring rare concomitant EGFR amplification and PTEN deletion, we used an integrative approach based on histopathologic and genomic characterization of the tumors, in-vitro drug HTS on PDCs and in-vivo validation of candidate drugs on PDXs.